Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Cash on Hand 2020–2024
Inhibikase Therapeutics Inc. annual/quarterly cash on hand history from 2021 to 2024. Cash on hand refers to the total amount of cash and cash equivalents held by a company.
- Inhibikase Therapeutics Inc. cash on hand for the quarter ending December 31, 2024 were 97.5M, a 959.78% increase year-over-year.
- Inhibikase Therapeutics Inc. cash on hand for 2024 were 97.5M, a 959.78% increase from 2023.
- Inhibikase Therapeutics Inc. cash on hand for 2023 were 9.2M, a 27.96% increase from 2022.
- Inhibikase Therapeutics Inc. cash on hand for 2022 were 7.2M, a 82.36% decrease from 2021.
- Inhibikase Therapeutics Inc. cash on hand for 2021 were 40.8M.
Cash on Hand
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Inhibikase Therapeutics Inc. Annual Cash on Hand (Millions of US $) | |
|---|---|
| 2024 | $98 |
| 2023 | $9 |
| 2022 | $7 |
| 2021 | $41 |
| Inhibikase Therapeutics Inc. Quarterly Cash on Hand (Millions of US $) | |
|---|---|
| 2024-12-31 | $98 |
| 2023-12-31 | $9 |
| 2022-12-31 | $7 |
| 2021-12-31 | $41 |
Inhibikase Therapeutics Inc. Cash on Hand — FAQ
Inhibikase Therapeutics Inc. (IKT) cash on hand over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's cash on hand history?
The chart and table above show Inhibikase Therapeutics Inc.'s cash on hand by year and by quarter, including the growth rate.